This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gryglewski, R. J. Articles by Blaszczyk, B. Search for Related Content PubMed PubMed Citation Articles by Gryglewski, R. J. Articles by Blaszczyk, B.

Stroke, Vol 14, 197-202, Copyright © 1983 by American Heart Association

ARTICLES

Treatment of ischaemic stroke with prostacyclin

RJ Gryglewski, S Nowak, E Kostka-Trabka, J Kusmiderski, A Dembinska-Kiec, K Bieron, M Basista and B Blaszczyk

Ten patients with ischaemic stroke were treated with prostacyclin (2.5- 5.0 ng/kg/min i.v. in 6 h courses 4-10 times during 1-2.5 days). In all patients a dramatic regression of hemiplegia, or hemiparesis, or aphasia occurred in the first few hours of prostacyclin infusion. Four to eight weeks later 6 patients left the clinic without neurological deficit; 3 patients had minor residual hemiparesis in upper limbs. In one patient, the occlusion of the contralateral carotid artery led to his death. It is considered that an antagonism may exist between endogenous cerebral prostanoids and prostacyclin and may have been responsible for the beneficial effects of prostacyclin therapy.

This article has been cited by other articles:

				Y. Cui, H. Takamatsu, T. Kakiuchi, H. Ohba, Y. Kataoka, C. Yokoyama, H. Onoe, Y. Watanabe, T. Hosoya, M. Suzuki, et al. Neuroprotection by a Central Nervous System-Type Prostacyclin Receptor Ligand Demonstrated in Monkeys Subjected to Middle Cerebral Artery Occlusion and Reperfusion: A Positron Emission Tomography Study Stroke, November 1, 2006; 37(11): 2830 - 2836. [Abstract] [Full Text] [PDF]